FDA patient workshop shows pain management still unmet need in fibromyalgia
Testimony from patients at an FDA workshop on fibromyalgia suggests drug developers aiming to reduce pain are on the right track, because many patients said existing drugs do not provide adequate relief.
Discussion at the patient-focused drug development workshop on March 26 also highlighted opportunities for new therapies that can treat a myriad of symptoms unlikely to be managed by a single drug.
Fibromyalgia is a chronic disorder that affects muscles and soft tissue. The etiology is unknown, and symptoms vary widely. However, the defining feature is chronic widespread pain, often perceived as areas called "tender points" or "trigger points."
In an online survey conducted during the meeting, the